Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 
 
 

Protagen and Bayer collaborate on diagnostic biomarkers for endometriosis
January 2012
SHARING OPTIONS:

DORTMUND, Germany—A new collaboration was established recently between in-vitro diagnostics specialist Protagen AG and Bayer HealthCare Pharmaceuticals for the clinical validation of diagnostic biomarkers for endometriosis. The agreement follows an endometriosis biomarker discovery study that took place last year, and is the third UNIarray Project within the collaboration between the two companies in the last three years. Endometriosis affects approximately 5 to 10 percent of women worldwide, and diagnosis is currently performed via laparoscopy. This new project aims to lead to predictive diagnosis through use of the UNIarray technology, which "is founded in the production of recombinant human proteins derived from tissue specific human expression libraries and spotted onto filter membranes," according to the company's website. The technology, it adds, enables "a broad, highly specific search for novel blood-based biomarkers."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.